NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed t ...

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Civitas Resources, Inc. (NYSE: CIVI) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Civitas you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/civitas-resources-inc. Investors have until July 1, 2025, to ask the Court to be appointe ...

SAN DIEGO, June 30, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"), have until August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers as well ...

SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), have until August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta and certain of Sarepta’s t ...

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in stock price following the termination of its partnership with Novo Nordisk [1][3]. Group 1: Lawsuit Details - The class action lawsuit, Sookdeo v. Hims & Hers Health, Inc., involves allegations that Hims & Hers and its executives violated the Securities Exchange Act of 1934 [1]. - The lawsuit claims that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy, which jeopardized patient safety [2]. - Following the announcement of the termination of the partnership with Novo Nordisk on June 23, 2025, Hims & Hers' stock price fell by more than 34% [3]. Group 2: Legal Process - Investors who purchased Hims & Hers securities during the class period (April 29, 2025, to June 23, 2025) can seek appointment as lead plaintiff in the class action lawsuit [4]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [4]. Group 3: Company Background - Hims & Hers is a telehealth company that provides prescription medications, over-the-counter medications, and personal care products [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Krispy Kreme, Inc. securities between February 25, 2025, and May 7, 2025, of the July 15, 2025, deadline to become a lead plaintiff in a class action lawsuit [1][2]. Group 1: Class Action Details - A class action lawsuit has been filed against Krispy Kreme, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. - To participate in the class action, investors must move the Court to serve as lead plaintiff by July 15, 2025 [2]. - The lawsuit alleges that Krispy Kreme made false and misleading statements regarding the demand for its products at McDonald's locations, which negatively impacted sales and the partnership's profitability [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [3]. - The firm has been recognized for its achievements in securities class action settlements, including a record settlement against a Chinese company and being ranked highly in the field since 2013 [3]. Group 3: Case Allegations - The lawsuit claims that Krispy Kreme's management failed to disclose a material decline in demand for its products at McDonald's, which was a key factor in declining average sales [4]. - It is alleged that the partnership with McDonald's was not profitable, leading to a pause in expansion efforts into new locations [4].

Core Viewpoint - A class action lawsuit has been filed against DoubleVerify Holdings, Inc. for alleged securities fraud and unlawful business practices, with investors encouraged to join the lawsuit by July 21, 2025 [1][2]. Financial Performance - On February 28, 2024, DoubleVerify lowered its revenue growth expectations for Q1 2024, leading to a stock price drop of $8.35, or 21.3%, closing at $30.89 on February 29, 2024 [4]. - On May 7, 2024, the company cut its full-year 2024 revenue outlook due to reduced ad spending from customers, resulting in a stock price decline of $11.79, or 38.6%, closing at $18.78 on May 8, 2024 [5]. - On February 27, 2025, DoubleVerify reported lower-than-expected Q4 2024 sales and earnings, with a stock price drop of approximately 36%, closing at $13.90 on February 28, 2025 [6]. Market Concerns - A report by Adalytics Research on March 28, 2025, claimed that DoubleVerify's advertisement verification services are ineffective, stating that customers are billed for ad impressions served to bots, which contradicts the company's claims [7].

Core Viewpoint - EchoStar Corporation is under investigation for potential securities fraud and unlawful business practices, which has led to significant stock price declines following various negative news reports and financial disclosures [1][3][4][5]. Group 1: Investigation and Legal Concerns - Pomerantz LLP is investigating claims on behalf of EchoStar investors regarding possible securities fraud or unlawful business practices by the company and its officers [1]. - The investigation follows a series of events that have raised concerns about EchoStar's compliance with federal requirements and its financial stability [3][4][5]. Group 2: Stock Price Impact - Following a Wall Street Journal article on May 12, 2025, regarding FCC investigations into EchoStar's compliance, the company's stock fell by $4.01, or 16.58%, closing at $20.18 [3]. - On May 30, 2025, EchoStar announced it would not make a $326 million interest payment on its senior spectrum secured notes, resulting in a stock price drop of $2.44, or 12.1%, to $17.73 [4]. - A report on June 6, 2025, indicated that EchoStar was considering a Chapter 11 bankruptcy filing, leading to a further decline in stock price by $1.49, or 8.52%, closing at $15.99 [5].

NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Rocket and certain ...

NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.    The investigation concerns whether Neogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On June 4, ...